<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Arrhythmogenic cardiomyopathy, as it has been recently redefined, is characterized by progressive myocyte loss with fibrosis and fat infiltration of the myocardium, which finally leads to a broad clinical spectrum ranging from heart failure symptoms to sudden cardiac death. The diagnosis of arrhythmogenic cardiomyopathy is challenging particularly because of its heterogeneity in presentation, which varies from focal right ventricular involvement to biventricular or prominent left ventricular phenotype. In the past decades, the development of new electrocardiographic and imaging diagnostic criteria for arrhythmogenic cardiomyopathy constituted an important area of research and resulted in the elaboration of the Padua criteria. However, even with the widespread availability of modern imaging techniques, there is still a lack of awareness in the health care community and this pathology persist in being under- or misdiagnosed. Given the limited indication of endomyocardial biopsy for the diagnosis of arrhythmogenic cardiomyopathy, one can conclude that the progress that has been made in the last few years in the multimodality imaging field is of utmost importance for the early detection and proper treatment of patients with arrhythmogenic cardiomyopathy, providing valuable prognostic information.</p>
</abstract>

Arrhythmogenic cardiomyopathy, as it has been recently redefined, is characterized by progressive myocyte loss with fibrosis and fat infiltration of the myocardium, which finally leads to a broad clinical spectrum ranging from heart failure symptoms to sudden cardiac death. The diagnosis of arrhythmogenic cardiomyopathy is challenging particularly because of its heterogeneity in presentation, which varies from focal right ventricular involvement to biventricular or prominent left ventricular phenotype. In the past decades, the development of new electrocardiographic and imaging diagnostic criteria for arrhythmogenic cardiomyopathy constituted an important area of research and resulted in the elaboration of the Padua criteria. However, even with the widespread availability of modern imaging techniques, there is still a lack of awareness in the health care community and this pathology persist in being under- or misdiagnosed. Given the limited indication of endomyocardial biopsy for the diagnosis of arrhythmogenic cardiomyopathy, one can conclude that the progress that has been made in the last few years in the multimodality imaging field is of utmost importance for the early detection and proper treatment of patients with arrhythmogenic cardiomyopathy, providing valuable prognostic information.

Multimodality imaging in arrhythmogenic cardiomyopathy

„Grigore T. Popa” University of Medicine and Pharmacy

Romanian Journal of Cardiology

This work is licensed under the Creative Commons Attribution 4.0 International License.

{"article-title":"Multimodality imaging in arrhythmogenic cardiomyopathy"}

Arrhythmogenic cardiomyopathy, as it has been recently redefined, is characterized by progressive myocyte loss with fibrosis and fat infiltration of the...

Multimodality imaging in arrhythmogenic cardiomyopathy

Article Category: Review

Online veröffentlicht: 30. Apr. 2022

Seitenbereich: 10 - 16

DOI: https://doi.org/10.47803/rjc.2021.31.1.10

Schlüsselwörter
multimodality imaging, arrhythmogenic cardiomyopathy, sudden cardiac death

© 2021 Laura Tapoi et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Multimodality imaging in arrhythmogenic cardiomyopathy

Article Category: Review

Online veröffentlicht: 30. Apr. 2022

Seitenbereich: 10 - 16

DOI: https://doi.org/10.47803/rjc.2021.31.1.10

Schlüsselwörtermultimodality imaging, arrhythmogenic cardiomyopathy, sudden cardiac death

© 2021 Laura Tapoi et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Schlüsselwörter
multimodality imaging, arrhythmogenic cardiomyopathy, sudden cardiac death